News Presentation ROTH Conference Presentation CRRT Presentation & Poster Stock Ticker Board Diversity Matrix SEC EDGAR
About Us Board of Directors Management Scientific Advisory Board Core Values
 

 

Screen Shot 2020-09-17 at 12.27.49 PM.png
Screen Shot 2020-09-17 at 12.29.32 PM.png

 

REVTx-99

REVTx-99, our lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS-CoV-2 infection. REVTx-99 is a proprietary intranasal formulation of phosphorylated hexaacylated disaccharide or PHAD™, a synthetic version of monophosphoryl lipid A. SARS-CoV-2 viral proteins have been shown to block the production of interferons, a key part of the innate immune response to viral infection, resulting in worse outcomes. REVTx-99 acts by stimulating the innate immune response via interaction with toll-like receptor 4 (TLR4) and activation of the TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway to produce protective cytokines including Type I and Type II interferons. The innate immune system is the first line of defense against invading pathogens such as bacteria and viruses. Toll-like receptors (TLRs) are associated with sentinel cells (e.g. macrophages, dendritic cells) and serve a vital role in the innate immune system response. TLRs recognize repeated molecular patterns associated with pathogens (PAMPS). When a pathogen invades a subject, TLRs recognize PAMPS as foreign and activate the innate immune response, inducing the production of numerous cytokines to combat the invading pathogen and stimulate the adaptive immune response. 

 

Phase 1 clinical study of REVTx-99 in healthy volunteers (RVL-HV01 study) has been approved by the Bellberry Human Research Ethics Committee (HREC) in Australia and is expected to begin in Q4 2020. Additional details about REVTx-99 can be found in our corporate presentation.  

 

 REVTx-200

REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Additional details about REVTx-200 can be found in our corporate presentation.

 

REVDx-501 

REVDx-501 is a diagnostic device in development for the detection of any respiratory viral infection (SARS-CoV-2, influenza A and B, parainfluenza, etc.) regardless of virus type without the need for specialized instrumentation. Additional details for REVDx-501 can be found in our corporate presentation.